trial

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCTId NCT01714713
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 830 (actual)
Sponsored by FORUM Pharmaceuticals Inc
Primary completion 2015-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
830 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-06
Primary completion
2015-10
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
EVP-6124

Sponsors

FORUM Pharmaceuticals IncLead Sponsor
Syneos HealthCollaborator

Sites

0 total

Linked catalysts

1
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cogni — primary completion2015-10

Facts & assertions

4 sourced
Enrollment
830
Phase
PHASE3
Primary Completion Date
2015-10
Status
COMPLETED
relationships
The graph out of here
drug
EVP-6124
drug
lead_sponsor
FORUM Pharmaceuticals Inc
company
collaborator
Syneos Health
company
indication
Schizophrenia
indication
Schizophrenia
indication
Impaired Cognition
indication